Q3 EPS Estimate for Caribou Biosciences Lifted by Analyst

Key Points

• Brookline Capital Management raised its Q3 2025 EPS estimate for Caribou Biosciences to ($0.36) from ($0.38), reflecting improved expectations for the company's financial performance.
• Caribou Biosciences reported a Q3 EPS of ($0.35), exceeding the consensus estimate of ($0.40) and generating revenue of $2.67 million, significantly higher than the expected $1.64 million.
• Institutional investors hold 77.51% of Caribou Biosciences' shares, indicating strong backing from hedge funds and investment firms in the company's potential.

Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) - Stock analysts at Brookline Capital Management raised their Q3 2025 EPS estimates for Caribou Biosciences in a research report issued to clients and investors on Tuesday, August 12th. Brookline Capital Management analyst L. Cann now expects that the company will post earnings of ($0.36) per share for the quarter, up from their prior forecast of ($0.38). The consensus estimate for Caribou Biosciences' current full-year earnings is ($1.64) per share. Brookline Capital Management also issued estimates for Caribou Biosciences' Q4 2025 earnings at ($0.41) EPS, FY2025 earnings at ($1.42) EPS, FY2026 earnings at ($0.97) EPS, FY2027 earnings at ($1.41) EPS and FY2028 earnings at $2.02 EPS.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.40) by $0.05. Caribou Biosciences had a negative return on equity of 62.35% and a negative net margin of 1,800.93%.The business had revenue of $2.67 million for the quarter, compared to the consensus estimate of $1.64 million.

Several other equities research analysts have also issued reports on the stock. Wall Street Zen lowered shares of Caribou Biosciences from a "hold" rating to a "sell" rating in a research note on Saturday. HC Wainwright restated a "buy" rating and set a $3.00 price target (down previously from $9.00) on shares of Caribou Biosciences in a research report on Monday, April 28th. Three equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $6.67.

Caribou Biosciences Stock Up 0.3%

Shares of CRBU stock traded up $0.0050 during mid-day trading on Friday, hitting $1.7750. 215,113 shares of the stock were exchanged, compared to its average volume of 1,341,246. The firm has a fifty day moving average of $1.69 and a 200 day moving average of $1.25. Caribou Biosciences has a 52-week low of $0.66 and a 52-week high of $2.9995. The company has a market cap of $165.29 million, a PE ratio of -1.00 and a beta of 2.55.

Institutional Trading of Caribou Biosciences

Hedge funds and other institutional investors have recently made changes to their positions in the company. Next Capital Management LLC acquired a new stake in shares of Caribou Biosciences during the 2nd quarter worth approximately $25,000. Creative Planning acquired a new stake in shares of Caribou Biosciences during the 2nd quarter worth approximately $25,000. Hudson Bay Capital Management LP acquired a new stake in Caribou Biosciences in the 2nd quarter valued at approximately $30,000. Savant Capital LLC purchased a new stake in Caribou Biosciences in the second quarter valued at approximately $36,000. Finally, Cerity Partners LLC lifted its stake in Caribou Biosciences by 163.6% during the first quarter. Cerity Partners LLC now owns 40,722 shares of the company's stock worth $37,000 after purchasing an additional 25,271 shares in the last quarter. Institutional investors and hedge funds own 77.51% of the company's stock.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.